文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

氟哌利多联合咪达唑仑与氟哌啶醇联合劳拉西泮治疗急诊科急性激越的前瞻性研究

Prospective study of haloperidol plus lorazepam versus droperidol plus midazolam for the treatment of acute agitation in the emergency department.
PubMed 文献 · Am J Emerg Med · 2022-02-25
一句话结论急诊急性未分化激越患者肌注氟哌利多5mg/咪达唑仑5mg在10分钟充分镇静比例上优于氟哌啶醇5mg/劳拉西泮2mg(51.2% vs 7%),但需氧补充比例更高。

这项前瞻性、非盲观察性研究在一所大学教学医院急诊科纳入86例对言语降级无效的急性未分化激越患者,分别肌注氟哌利多5mg/咪达唑仑5mg或氟哌啶醇5mg/劳拉西泮2mg。主要终点为10分钟时充分镇静(ED SAT评分≤0)的比例,氟哌利多/咪达唑仑组为51.2%,氟哌啶醇/劳拉西泮组为7%(OR 14;95%CI 3.7, 52.1)。氟哌利多/咪达唑仑组中位充分镇静时间为10分钟,氟哌啶醇/劳拉西泮组为30分钟。氟哌利多/咪达唑仑组11例(25.6%)需氧补充,氟哌啶醇/劳拉西泮组4例(9.3%);无患者出现锥体外系症状或需气管插管。

要点

  • 对言语降级无效的急诊急性未分化激越患者,肌注氟哌利多5mg/咪达唑仑5mg在10分钟时充分镇静(ED SAT≤0)比例51.2%,高于肌注氟哌啶醇5mg/劳拉西泮2mg的7%(OR 14;95%CI 3.7, 52.1)。
  • 氟哌利多/咪达唑仑组中位充分镇静时间10分钟,氟哌啶醇/劳拉西泮组30分钟。
  • 氟哌利多/咪达唑仑组11例(25.6%)需氧补充,氟哌啶醇/劳拉西泮组4例(9.3%);无患者需气管插管或出现锥体外系症状。
  • 本研究为非盲观察性研究,作者认为氟哌利多/咪达唑仑组患者可能更可能需要氧补充。

适用人群与场景

  • 急诊科急性未分化激越、对言语降级无效的患者。

诊断标准与关键阈值

  • 充分镇静定义为急诊镇静评估工具(ED SAT)评分≤0。

处置流程与药物剂量

  • 肌注氟哌利多5mg/咪达唑仑5mg。
  • 肌注氟哌啶醇5mg/劳拉西泮2mg。

研究设计与关键结果

  • 前瞻性、非盲观察性研究,单所大学教学医院急诊科,共纳入86例,氟哌利多/咪达唑仑组43例,氟哌啶醇/劳拉西泮组43例。
  • 10分钟时充分镇静(ED SAT≤0)比例:氟哌利多/咪达唑仑组51.2% vs 氟哌啶醇/劳拉西泮组7%(OR 14;95%CI 3.7, 52.1)。
  • 中位充分镇静时间:氟哌利多/咪达唑仑组10分钟 vs 氟哌啶醇/劳拉西泮组30分钟。
  • 需氧补充:氟哌利多/咪达唑仑组11例(25.6%) vs 氟哌啶醇/劳拉西泮组4例(9.3%)。
  • 无患者出现锥体外系症状或需气管插管。

证据类型、等级与局限

  • 证据类型:前瞻性、非盲观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对急诊急性未分化激越且言语降级无效的患者,肌注氟哌利多/咪达唑仑较肌注氟哌啶醇/劳拉西泮在10分钟时更可能达到充分镇静(ED SAT≤0)。
  • 作者认为氟哌利多/咪达唑仑组患者可能更可能需要氧补充。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVES: The objective of this study was to compare the combination of intramuscular (IM) droperidol/midazolam to haloperidol/lorazepam regarding time to sedation in patients with acute undifferentiated agitation in the emergency department (ED).

METHODS: This was a prospective, unblinded observational study in the ED of a university teaching hospital. Subjects with acute undifferentiated agitation refractory to verbal de-escalation were assigned to receive a combination of either haloperidol 5 mg/lorazepam 2 mg or droperidol 5 mg/midazolam 5 mg IM. The primary outcome was the proportion of patients adequately sedated at 10 min defined as ED Sedation Assessment Tool (SAT) score of 0 or less. Secondary outcomes included change in ED SAT score at 5, 15, 30, and 60 min, the need for oxygen supplementation, and the need for airway intervention.

RESULTS: A total of 86 patients were enrolled in the study, with 43 patients receiving droperidol/midazolam and 43 patients receiving haloperidol/lorazepam. Ten minutes after receiving medication, 51.2% of patients in the droperidol/midazolam group were adequately sedated compared to 7% of patients in the haloperidol/lorazepam group (OR: 14; 95% CI: 3.7, 52.1). Median time to adequate sedation was 10 min for the droperidol/midazolam group and 30 min for the haloperidol/lorazepam group. Eleven patients (25.6%) in the droperidol/midazolam group received oxygen supplementation compared to four patients (9.3%) in the haloperidol/lorazepam group. No study patients experienced extrapyramidal symptoms or required endotracheal intubation.

CONCLUSION: Intramuscular droperidol/midazolam was superior to intramuscular haloperidol/lorazepam in achieving adequate sedation at 10 min. Patients in the droperidol/midazolam arm may be more likely to receive oxygen supplementation than those in the haloperidol/lorazepam arm.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Thiemann P, Roy D, Huecker M, et al. Prospective study of haloperidol plus lorazepam versus droperidol plus midazolam for the treatment of acute agitation in the emergency department. Am J Emerg Med. 2022. PMID: 35287091. doi:10.1016/j.ajem.2022.02.042

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。